The algorithm of evaluation of interchangeability of pharmaceuticals


Cite item

Full Text

Abstract

The article presents originally developed algorithm of expertise of interchangeability of pharmaceuticals for medical application. The interchangeable pharmaceutical is a pharmaceutical with evidenced therapeutic equivalence or bioequivalence concerning reference (original) pharmaceutical with equivalent qualitative and quantitative compound of active substances, auxiliary substances, medicinal form, identical way of administration and mode of application and manufactured according requirements of rules of proper processing practice. The interchangeability of pharmaceutical to reference pharmaceutical is established during state registration of pharmaceutical or at introduction of changes into documents contained in registration dossier of already registered pharmaceutical in the Russian Federation. The application about establishment of interchangeability by applicant - holder or owner of registration certification of pharmaceutical for medical application is required.

About the authors

Boris K. Romanov

The research center of expertise of means of medical application of Minzdrav of Russia

Email: Romanov@expmed.ru
MD, PHD, DSc 127051 Moscow, Russia

I. V Sakaeva

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

N. D Bunyatyan

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

A. N Vasilyev

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

V. P Bondarev

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

A. B Prokofyev

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

R. I Yagudina

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

R. N Alyautdin

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

E. L Kovaleva

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

A. P Pereversev

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

K. E Zatolochina

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

A. S Kazakov

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

A. V Komratov

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

K. A Koshechkin

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

E. Yu Pasternak

The research center of expertise of means of medical application of Minzdrav of Russia

127051 Moscow, Russia

References

  1. Федеральный закон от 22.12.2014 № 429-ФЗ «О внесении изменений в Федеральный закон "Об обращении лекарственных средств"». М.; 2014.
  2. Сводный отчет о проведении оценки регулирующего воздействия (Цит. по http://regulation.gov.ru/project/22466.html, дата обращения - 12.01.2015).
  3. Федеральный закон от 12.04.2010 № 61-ФЗ (ред. от 22.10.2014) "Об обращении лекарственных средств" (с изм. и доп.). М.; 2014.
  4. Лепахин В.К., Романов Б.К., Никитина Т.Н., Снегирева И.И. Экспертиза оценки отношения ожидаемой пользы к возможному риску применения лекарственых средств. Ведомости Научного центра экспертизы средств медицинского применения. 2012; 2: 19-21.
  5. Truus Janse-de Hoog. Interchangeability of generics. European Medicines Agency. URL:http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2011/06/WC500107873.pdf. (Accessed 12 January 2015).
  6. Approved Drug Products with Therapeutic Equivalence Evaluations, 34nd (2014) [Orange Book]. United States Food and Drug Administration / URL: http://www.accessdata.fda.gov/scripts/cder/ob. (Accessed 12 January 2015).
  7. Guidance for Industry on Biosimilars: Q & As Regarding Implementation of the BPCI Act of 2009 (Draft Guidance Updated for 508 on 3/22/12). Food and Drug Administration. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatory Information/Guidances/ucm259797.htm. (Accessed 12 January 2015).

Copyright (c) 2015 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies